199 related articles for article (PubMed ID: 35359973)
1. A Metabolism-Related Gene Landscape Predicts Prostate Cancer Recurrence and Treatment Response.
Zhou L; Fan R; Luo Y; Zhang C; Jia D; Wang R; Zeng Y; Ren M; Du K; Pan W; Yang J; Tian F; Gu C
Front Immunol; 2022; 13():837991. PubMed ID: 35359973
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
3. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
4. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract][Full Text] [Related]
5. A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer.
Guo T; Wang J; Yan S; Meng X; Zhang X; Xu S; Ren S; Huang Y
Front Endocrinol (Lausanne); 2022; 13():1037099. PubMed ID: 36339430
[TBL] [Abstract][Full Text] [Related]
6. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
Li X; Zheng C; Xue X; Wu J; Li F; Song D; Li X
Funct Integr Genomics; 2023 Apr; 23(2):115. PubMed ID: 37010617
[TBL] [Abstract][Full Text] [Related]
8. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-EchevarrÃa MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
9. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
11. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
12. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
[TBL] [Abstract][Full Text] [Related]
13. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
14. Identification of a basement membrane gene signature for predicting prognosis and estimating the tumor immune microenvironment in prostate cancer.
Xie T; Fu DJ; Li KJ; Guo JD; Xiao ZM; Li Z; Zhao SC
Aging (Albany NY); 2024 Jan; 16(2):1581-1604. PubMed ID: 38240702
[TBL] [Abstract][Full Text] [Related]
15. The m
Li C; Peng D; Gan Y; Zhou L; Hou W; Wang B; Yuan P; Xiong W; Wang L
Front Immunol; 2023; 14():1086907. PubMed ID: 37033963
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
18. Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model.
Zhang Y; Zhang R; Liang F; Zhang L; Liang X
Front Oncol; 2020; 10():598801. PubMed ID: 33324566
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence.
Fu M; Wang Q; Wang H; Dai Y; Wang J; Kang W; Cui Z; Jin X
Front Genet; 2021; 12():639642. PubMed ID: 34490029
[TBL] [Abstract][Full Text] [Related]
20. Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy.
Feng D; Shi X; Zhang F; Xiong Q; Wei Q; Yang L
Front Immunol; 2022; 13():839362. PubMed ID: 35280985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
